These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12969987)

  • 1. Inhibitory effect of imatinib on normal progenitor cells in vitro.
    Bartolovic K; Balabanov S; Hartmann U; Komor M; Boehmler AM; Bühring HJ; Möhle R; Hoelzer D; Kanz L; Hofmann WK; Brümmendorf TH
    Blood; 2004 Jan; 103(2):523-9. PubMed ID: 12969987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.
    Belle L; Bruck F; Foguenne J; Gothot A; Beguin Y; Baron F; Briquet A
    PLoS One; 2012; 7(12):e52564. PubMed ID: 23285088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
    Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
    Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
    Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
    Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
    Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
    Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
    Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
    Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
    Holtz MS; Bhatia R
    Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
    Korycka A; Robak T
    Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion of CD34+ umbilical cord blood cells in a defined serum-free medium (QBSF-60) with early effect cytokines.
    Qiu L; Meagher R; Welhausen S; Heye M; Brown R; Herzig RH
    J Hematother Stem Cell Res; 1999 Dec; 8(6):609-18. PubMed ID: 10645768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.
    Soares PB; Jeremias TS; Alvarez-Silva M; Licinio MA; Santos-Silva MC; Vituri CL
    Braz J Med Biol Res; 2013 Jan; 46(1):39-51. PubMed ID: 23011404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS; Forman SJ; Bhatia R
    Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Harata M; Soda Y; Tani K; Ooi J; Takizawa T; Chen M; Bai Y; Izawa K; Kobayashi S; Tomonari A; Nagamura F; Takahashi S; Uchimaru K; Iseki T; Tsuji T; Takahashi TA; Sugita K; Nakazawa S; Tojo A; Maruyama K; Asano S
    Blood; 2004 Sep; 104(5):1442-9. PubMed ID: 15155467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.